Skip to main content

Table 4 Association of modified staging system and AJCC staging system with survival in patients with prostate cancer in the training set and testing set

From: Modified the 8th AJCC staging system for patients with advanced prostate cancer: a study based on SEER database

 

Model 1

Model 2

Model 3

 h (95%CI)

P

HR (95%CI)

P

HR (95%CI)

P

Training set

      

Modified stage

      

III B

Ref

     

III C

2.32 (1.64–3.28)

< 0.001

2.03 (1.43–2.87)

< 0.001

2.06 (1.46–2.92)

< 0.001

IV A

11.35 (8.00-16.10)

< 0.001

8.56 (6.03–12.16)

< 0.001

6.91 (4.81–9.94)

< 0.001

IV B

65.89 (46.45–93.48)

< 0.001

42.71 (29.98–60.85)

< 0.001

21.89 (14.76–32.46)

< 0.001

AJCC 8th stage

      

III B

Ref

     

III C

5.34 (4.36–6.54)

< 0.001

4.31 (3.51–5.29)

< 0.001

4.17 (3.39–5.13)

< 0.001

IV A

2.44 (2.07–2.88)

< 0.001

2.42 (2.05–2.85)

< 0.001

0.64 (0.35–1.15)

0.132

IV B

22.49 (20.04–25.25)

< 0.001

16.42 (14.52–18.56)

< 0.001

3.19 (1.79–5.69)

< 0.001

Testing set

      

Modified stage

      

III B

Ref

     

III C

2.34 (1.52–3.60)

< 0.001

2.10 (1.36–3.23)

< 0.001

2.18 (1.41–3.35)

< 0.001

IV A

13.96 (9.06–21.50)

< 0.001

10.55 (6.83–16.30)

< 0.001

9.17 (5.85–14.37)

< 0.001

IV B

66.18 (42.87-102.17)

< 0.001

43.81 (28.22–68.01)

< 0.001

25.83 (15.85–42.08)

< 0.001

AJCC 8th stage

      

III B

      

III C

4.43 (3.43–5.71)

< 0.001

3.48 (2.69–4.50)

< 0.001

3.21 (2.47–4.17)

< 0.001

IV A

2.75 (2.27–3.33)

< 0.001

2.74 (2.26–3.31)

< 0.001

1.82 (0.74–4.49)

0.194

IV B

20.41 (17.70-23.52)

< 0.001

14.39 (12.37–16.73)

< 0.001

6.92 (2.83–16.87)

< 0.001

  1. Note: HR, hazard ratio; CI, confidence interval; model 1, univariable analysis; model 2, multivariable analysis model that adjusted for age, race, marital status, and insurance status; model 3, multivariable analysis model that adjusted for age, race, marital status, insurance status, and stage
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us